CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
9.18
4.06%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Altimmune Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 8.86
Open* 8.89
1-Year Change* -23.1%
Day's Range* 8.85 - 9.34
52 wk Range 2.09-15.95
Average Volume (10 days) 8.54M
Average Volume (3 months) 219.79M
Market Cap 579.73M
P/E Ratio -100.00K
Shares Outstanding 53.73M
Revenue 279.00K
EPS -1.57
Dividend (Yield %) N/A
Beta 0.01
Next Earnings Date Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 23, 2024 9.18 0.44 5.03% 8.74 9.40 8.69
Feb 22, 2024 8.86 0.69 8.45% 8.17 8.91 8.02
Feb 21, 2024 8.20 0.00 0.00% 8.20 8.35 8.02
Feb 20, 2024 8.39 -0.03 -0.36% 8.42 8.82 8.28
Feb 16, 2024 8.74 -0.04 -0.46% 8.78 8.94 8.57
Feb 15, 2024 8.90 0.00 0.00% 8.90 9.59 8.81
Feb 14, 2024 8.99 0.26 2.98% 8.73 9.31 8.34
Feb 13, 2024 8.43 -1.37 -13.98% 9.80 9.86 7.99
Feb 12, 2024 10.38 0.00 0.00% 10.38 10.54 10.03
Feb 9, 2024 10.43 0.62 6.32% 9.81 10.84 9.70
Feb 8, 2024 9.63 -0.55 -5.40% 10.18 10.46 9.51
Feb 7, 2024 10.33 0.19 1.87% 10.14 10.54 9.98
Feb 6, 2024 10.60 1.39 15.09% 9.21 10.89 9.19
Feb 5, 2024 9.37 0.27 2.97% 9.10 9.48 8.94
Feb 2, 2024 9.31 -0.24 -2.51% 9.55 9.92 9.23
Feb 1, 2024 9.86 0.48 5.12% 9.38 10.08 9.32
Jan 31, 2024 9.43 -0.23 -2.38% 9.66 10.05 9.33
Jan 30, 2024 9.76 -0.05 -0.51% 9.81 10.04 9.49
Jan 29, 2024 10.12 0.92 10.00% 9.20 10.12 8.75
Jan 26, 2024 9.31 -0.06 -0.64% 9.37 9.59 9.19

Altimmune, Inc. Events

Time (UTC) Country Event
Monday, February 26, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Altimmune Inc Earnings Release
Q4 2023 Altimmune Inc Earnings Release

Forecast

-

Previous

-
Thursday, May 9, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Altimmune Inc Earnings Release
Q1 2024 Altimmune Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue -0.068 4.41036 8.18503 5.8014 10.3312
Revenue -0.068 4.41036 8.18503 5.8014 10.3312
Total Operating Expense 87.672 101.324 62.9838 27.2663 53.1656
Selling/General/Admin. Expenses, Total 17.134 15.4133 13.2094 8.50078 9.76558
Research & Development 70.538 74.5212 49.7275 17.618 18.3757
Unusual Expense (Income) 0 11.37 0 1 24.9407
Operating Income -87.74 -96.914 -54.7987 -21.4649 -42.8344
Interest Income (Expense), Net Non-Operating 2.862 0.19708 0.31309 0.87117 -2.76442
Other, Net -0.032 -0.37387 0.02415 0.01514 0.27789
Net Income Before Taxes -84.91 -97.0908 -54.4615 -20.5786 -45.3209
Net Income After Taxes -84.713 -97.0908 -49.0445 -20.5201 -39.1712
Net Income Before Extra. Items -84.713 -97.0908 -49.0445 -20.5201 -39.1712
Net Income -84.713 -97.0908 -49.0445 -20.5201 -39.1712
Total Adjustments to Net Income 0 -0.45293 -3.3078
Income Available to Common Excl. Extra. Items -84.713 -97.0908 -49.0445 -20.9731 -42.479
Income Available to Common Incl. Extra. Items -84.713 -97.0908 -49.0445 -20.9731 -42.479
Diluted Net Income -84.713 -97.0908 -49.0445 -20.9731 -42.479
Diluted Weighted Average Shares 46.9263 41.2835 25.637 13.125 2.80238
Diluted EPS Excluding Extraordinary Items -1.80523 -2.35181 -1.91303 -1.59795 -15.1582
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -1.80523 -2.07639 -1.91303 -1.54843 -9.37328
Depreciation / Amortization 0.01992 0.04681 0.1475 0.08365
Total Extraordinary Items 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.006 0.021 -0.068 0.002 0.008
Revenue 0.006 0.021 -0.068 0.002 0.008
Total Operating Expense 18.013 21.78 87.672 24.754 20.403
Selling/General/Admin. Expenses, Total 4.76 4.531 17.134 4.492 4.41
Research & Development 13.253 17.249 70.538 20.262 15.993
Operating Income -18.007 -21.759 -87.74 -24.752 -20.395
Interest Income (Expense), Net Non-Operating 1.833 1.666 2.862 0.989 0.263
Other, Net 0.113 0.019 -0.032 0.05 0.025
Net Income Before Taxes -16.061 -20.074 -84.91 -23.713 -20.107
Net Income After Taxes -16.061 -20.074 -84.713 -23.516 -20.107
Net Income Before Extra. Items -16.061 -20.074 -84.713 -23.516 -20.107
Net Income -16.061 -20.074 -84.713 -23.516 -20.107
Income Available to Common Excl. Extra. Items -16.061 -20.074 -84.713 -23.516 -20.107
Income Available to Common Incl. Extra. Items -16.061 -20.074 -84.713 -23.516 -20.107
Diluted Net Income -16.061 -20.074 -84.713 -23.516 -20.107
Diluted Weighted Average Shares 50.6916 50.1257 46.9263 49.2865 47.5026
Diluted EPS Excluding Extraordinary Items -0.31684 -0.40047 -1.80523 -0.47713 -0.42328
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.31684 -0.40047 -1.80523 -0.47713 -0.42328
Unusual Expense (Income) 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 192.813 204.126 230.257 39.3947 39.3721
Cash and Short Term Investments 184.88 190.301 215.923 37.2401 33.7187
Cash & Equivalents 111.097 190.301 115.918 8.96269 33.7187
Total Receivables, Net 2.541 5.83848 12.373 1.65028 4.47091
Accounts Receivable - Trade, Net 0.173 0.42884 4.6102 1.02118 3.46194
Prepaid Expenses 5.358 7.95269 1.92668 0.47023 0.54809
Other Current Assets, Total 0.034 0.03417 0.03417 0.03417 0.63442
Total Assets 206.928 218.865 245.115 54.058 54.7505
Property/Plant/Equipment, Total - Net 1.677 2.24596 1.96075 1.80253 1.3428
Property/Plant/Equipment, Total - Gross 3.175 4.29284 3.55956 3.1501 2.45055
Accumulated Depreciation, Total -1.498 -2.04688 -1.59881 -1.34757 -1.10775
Goodwill, Net
Intangibles, Net 12.419 12.419 12.8238 12.7322 13.8519
Other Long Term Assets, Total 0.019 0.0738 0.07341 0.12855 0.18368
Total Current Liabilities 17.054 18.2759 12.0204 3.923 4.52741
Accounts Payable 4.804 2.03449 0.61229 0.01823 0.37286
Accrued Expenses 11.081 10.1514 11.3884 3.8432 4.0632
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.169 6.09 0.01975 0.06156 0.01975
Total Liabilities 21.635 19.7301 19.2389 8.53787 6.43798
Total Long Term Debt 0 0 0 0 0.50117
Long Term Debt 0 0.50117
Deferred Income Tax 0.0585
Other Liabilities, Total 4.581 1.4542 7.21844 4.61488 1.3509
Total Equity 185.293 199.135 225.876 45.5201 48.3126
Redeemable Preferred Stock 0
Common Stock 0.005 0.00409 0.0037 0.00151 0.00088
Additional Paid-In Capital 568.399 497.342 417.338 187.915 170.208
Retained Earnings (Accumulated Deficit) -377.884 -293.171 -186.421 -137.376 -116.856
Other Equity, Total -5.227 -5.04016 -5.04452 -5.02016 -5.04016
Total Liabilities & Shareholders’ Equity 206.928 218.865 245.115 54.058 54.7505
Total Common Shares Outstanding 49.1998 40.9938 37.1429 15.3122 9.07824
Current Port. of LT Debt/Capital Leases 0 0.0716
Short Term Investments 73.783 0 100.006 28.2774
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 152.964 169.532 173.111 192.813 211.004
Cash and Short Term Investments 140.779 159.954 165.729 184.88 201.827
Cash & Equivalents 86.855 102.352 104.69 111.097 127.465
Short Term Investments 53.924 57.602 61.039 73.783 74.362
Total Receivables, Net 4.529 3.715 3.37 2.541 4.353
Accounts Receivable - Trade, Net 0.876 0.136 0.252 0.173 0.633
Prepaid Expenses 7.615 5.822 3.978 5.358 4.79
Other Current Assets, Total 0.041 0.041 0.034 0.034 0.034
Total Assets 166.573 183.316 187.083 206.928 225.277
Property/Plant/Equipment, Total - Net 1.189 1.366 1.548 1.677 1.821
Property/Plant/Equipment, Total - Gross 3.175
Accumulated Depreciation, Total -1.498
Intangibles, Net 12.419 12.419 12.419 12.419 12.419
Other Long Term Assets, Total 0.001 -0.001 0.005 0.019 0.033
Total Current Liabilities 11.871 11.437 14.951 17.054 15.742
Accounts Payable 3.046 4.035 5.238 4.804 1.419
Accrued Expenses 8.825 7.346 8.544 11.081 13.154
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 0.056 1.169 1.169 1.169
Total Liabilities 16.176 15.602 19.351 21.635 20.248
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 4.305 4.165 4.4 4.581 4.506
Total Equity 150.397 167.714 167.732 185.293 205.029
Common Stock 0.005 0.005 0.005 0.005 0.005
Additional Paid-In Capital 590.206 586.908 570.786 568.399 566.551
Retained Earnings (Accumulated Deficit) -434.69 -414.019 -397.958 -377.884 -356.224
Other Equity, Total -5.124 -5.18 -5.101 -5.227 -5.303
Total Liabilities & Shareholders’ Equity 166.573 183.316 187.083 206.928 225.277
Total Common Shares Outstanding 52.8589 52.6577 49.2867 49.1998 49.1616
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -84.713 -97.0908 -49.0445 -20.5201 -39.1712
Cash From Operating Activities -62.586 -78.2379 -34.3058 -9.602 -9.38891
Cash From Operating Activities 0.5513 0.42888 0.23982 0.21872
Amortization 0.1475 0.08365
Non-Cash Items 8.016 18.5521 18.8219 8.76996 28.6495
Cash Taxes Paid 0 0.00179 0 0.05721
Changes in Working Capital 14.111 -0.25053 -4.51216 1.81936 6.98019
Cash From Investing Activities -73.399 87.5231 -72.2258 -28.2864 -1.00114
Capital Expenditures -0.126 -12.3117 -0.34242 -0.029 -1.01563
Other Investing Cash Flow Items, Total -73.273 99.8348 -71.8834 -28.2574 0.01449
Cash From Financing Activities 56.781 65.0978 213.487 12.5321 32.4899
Financing Cash Flow Items 0 -0.11852 0
Issuance (Retirement) of Stock, Net 56.781 65.2163 213.487 12.8241 34.0396
Issuance (Retirement) of Debt, Net 0 0 -0.292 -1.5497
Foreign Exchange Effects -0.05037
Net Change in Cash -79.204 74.383 106.955 -25.3563 22.0495
Deferred Taxes -0.0585 -6.14979
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -20.074 -84.713 -63.053 -39.537 -19.43
Cash From Operating Activities -19.407 -62.586 -45.28 -30.23 -13.526
Cash From Operating Activities 0.031 0.172 0.119
Non-Cash Items 2.301 8.016 6.112 4.033 0.143
Changes in Working Capital -1.634 14.111 11.63 5.102 5.642
Cash From Investing Activities 13.302 -73.399 -74.38 -48.977 -0.009
Capital Expenditures -0.051 -0.126 -0.088 -0.028 -0.009
Other Investing Cash Flow Items, Total 13.353 -73.273 -74.292 -48.949 0
Cash From Financing Activities -0.302 56.781 56.824 24.764 3.181
Financing Cash Flow Items -0.013 0 0 -0.036 -0.119
Issuance (Retirement) of Stock, Net -0.289 56.781 56.824 24.8 3.3
Net Change in Cash -6.407 -79.204 -62.836 -54.443 -10.354
Cash Taxes Paid
Issuance (Retirement) of Debt, Net
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Nuveen LLC Pension Fund 6.5652 3458949 190888 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.3801 3361432 2049696 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.2748 3305972 780859 2023-06-30 LOW
Tang Capital Management, LLC Hedge Fund 5.2196 2750000 0 2023-06-30 MED
Marshall Wace LLP Investment Advisor/Hedge Fund 3.9086 2059290 462160 2023-06-30 HIGH
Two Sigma Investments, LP Hedge Fund 3.6909 1944620 -84362 2023-06-30 HIGH
Laurion Capital Management LP Hedge Fund 3.4916 1839604 -1661726 2023-06-30 HIGH
Avidity Partners Management LP Hedge Fund 2.2285 1174100 -141100 2023-06-30 HIGH
Ardsley Advisory Partners LP Hedge Fund 1.9778 1042050 -405200 2023-06-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.8408 969861 487500 2023-06-30 LOW
Millennium Management LLC Hedge Fund 1.7881 942094 -126651 2023-06-30 HIGH
Qube Research & Technologies Ltd Hedge Fund 1.7277 910239 227559 2023-06-30 HIGH
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.5261 804073 -4155181 2023-06-30 LOW
Balyasny Asset Management LP Hedge Fund 1.3277 699527 208839 2023-06-30 HIGH
Renaissance Technologies LLC Hedge Fund 1.2502 658700 382400 2023-06-30 HIGH
D. E. Shaw & Co., L.P. Hedge Fund 0.9571 504238 504238 2023-06-30 MED
Sphera Funds Management Ltd. Hedge Fund 0.949 500000 200000 2023-06-30 LOW
Walleye Capital LLC Hedge Fund 0.7968 419783 372544 2023-06-30 HIGH
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.7106 374396 257680 2023-06-30 LOW
Morgan Stanley & Co. LLC Research Firm 0.6581 346724 -127692 2023-06-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Altimmune, Inc. Company profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Industry: Bio Therapeutic Drugs

910 Clopper Rd Ste 201S
GAITHERSBURG
MARYLAND 20878-1361
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

US100

17,914.30 Price
-0.300% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 7.0

Gold

2,035.76 Price
+0.560% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 22:00 (UTC)
Spread 0.50

XRP/USD

0.55 Price
+0.780% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

76.56 Price
-2.240% 1D Chg, %
Long position overnight fee 0.0163%
Short position overnight fee -0.0382%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading